Jamjoom Pharmaceuticals Factory Co. — Proxy Solicitation & Information Statement 2026

May 20, 2026

Jamjoom Pharmaceuticals Factory Co. Board invites its shareholders to attend the Extraordinary General Assembly Meeting (First Meeting) via modern technology means

4015 · 20/05/2026 08:21:46 · Announcement #95536 · View on Saudi Exchange

Jamjoom Pharmaceuticals Factory Co. Board invites its shareholders to attend the Extraordinary General Assembly Meeting (First Meeting) via modern technology means

Element List	Explanation
Introduction	The Board of Directors of Jamjoom Pharmaceuticals Factory Company (the “Company”) is pleased to invite its esteemed shareholders to participate and vote in the Extraordinary General Assembly Meeting (First Meeting and Second Meeting one hour later), which is scheduled to be held at 8:30 PM on Monday, 29 Dhul-Hijjah 1447H, corresponding to 15/06/2026 via modern technology means.
City and Location of the General Assembly's Meeting	Jeddah – Sari Street – Company headquarters – via modern technology means (using Tadawulaty system).
Hyperlink of the Meeting Location	Click Here
Date of the General Assembly's Meeting	2026-06-15 Corresponding to 1447-12-29
Time of the General Assembly’s Meeting	20:30
Methodology of Convening the General Assembly’s Meeting	Via modern technology means
Attendance Eligibility, Registration Eligibility, and Voting End	Shareholders who are registered in the issuers shareholders record at the Depositary Center by the end of the trade session prior to the general assembly meeting and in accordance with the laws and regulations. The shareholder has the right to delegate whomever other than the board of directors. The right to register a name to attend the general assembly meeting ends at the time of convening the general assembly meeting. The attendees right to vote on the items of the assembly’s agenda ends upon the end of screening the votes by the Screening Committee.
Quorum for Convening the General Assembly's Meeting	In accordance with Article (34) of the Company’s Bylaws, an Extraordinary General Assembly meeting shall be valid if attended by shareholders representing at least one-half of the Company’s voting shares. If the required quorum is not met, a second meeting shall be held one hour after the end of the period specified for the first meeting, and the second meeting shall be deemed valid if attended by shareholders representing at least one-quarter of the Company’s voting shares
General Assembly Meeting Agenda	Attached
Proxy Form
The shareholder right in discussing the assembly agenda topics, asking questions, and exercising the voting right	Shareholders are entitled to discuss items listed in the agenda of the General Assembly and raise relevant questions to the Board members, noting that the voting is free of charge for all Shareholders via: http://tadawulaty.com.sa
Details of the electronic voting on the Assembly’s agenda	Shareholders registered in the Tadawulaty services will be able to vote remotely, on the items of the Extraordinary General Assembly meeting. starting from 1:00AM on Thursday, 11/06/2026G corresponding to 25/12/1447 H until the end of the meeting. Please note that registration in Tadawulaty service and voting are free of charge for all shareholders using the following link:

www.tadawulaty.com.sa Method of Communication in Case of Any Enquiries For any questions, kindly contact the Investor Relations Department during business hours from 09:00 AM to 05:00 PM at:

Tel: +966 12 614 0099 ext. 3313

Email: ir@jamjoompharma.com Attached Documents              

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.